Assembly of the epstein-barr virus BBLF4, BSLF1 and BBLF2/3 proteins and their interactive properties.
Epstein-Barr virus (EBV) encodes putative helicase-primase proteins BBLF4, BSLF1 and BBLF2/3, which are essential for the lytic phase of viral DNA replication. The BSLF1, BBLF4 and BBLF2/3 proteins were expressed in B95-8 cells after induction of a virus productive cycle, possessing apparent molecular masses of 89 kDa, 90 kDa and 80 kDa, respectively. The anti-BSLF1 or anti-BBLF2/3 protein-specific antibody, which recognizes its target protein in both Western blotting and immunoprecipitation analyses, immunoprecipitated all of the BSLF1, BBLF4 and BBLF2/3 proteins from the extract of the cells with a virus productive cycle, indicating that these viral proteins are assembled together in vivo. To characterize their protein-protein interactions in detail, recombinant baculoviruses capable of expressing each of these viral gene products in insect cells were constructed. The assembly of the three virus replication proteins was reproduced in insect cells co- infected with the three recombinant baculoviruses, indicating that complex formation does not require other EBV replication proteins. Furthermore, experiments performed by using the extracts from insect cells co-infected with each pair of the recombinant viruses demonstrated that the BSLF1 protein could interact separately with both the BBLF4 and BBLF2/3 proteins and that the BBLF2/3 protein also interacted with the BBLF4 protein. These observations strongly suggest that within the BBLF4-BSLF1-BBLF2/3 complex each component interacts directly with the other two, resulting in helicase-primase enzyme activity.
Yokoyama
Naoaki
N
Division of Virology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan1.
Fujii
Ken
K
Division of Virology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan1.
Hirata
Mineo
M
Division of Virology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan1.
Tamai
Katsuyuki
K
Research and Development Department, Medical and Biological Laboratories, Ohara, Terasawaoka, Ina 396-0002, Japan2.
Kiyono
Tohru
T
Division of Virology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan1.
Kuzushima
Kiyotaka
K
Division of Virology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan1.
Nishiyama
Yukihiro
Y
Laboratory of Virology, Nagoya University School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan3.
Fujita
Masatoshi
M
Division of Virology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan1.
Tsurumi
Tatsuya
T
Division of Virology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan1.
D000818:Animals; D016367:Baculoviridae / Q000235:genetics; D004265:DNA Helicases / Q000502:physiology*; D019915:DNA Primase / Q000502:physiology*; D004261:DNA Replication; D004854:Herpesvirus 4, Human / Q000502:physiology*; D011817:Rabbits; D018411:Spodoptera; D014764:Viral Proteins / Q000502:physiology*; D019065:Virus Assembly; D014779:Virus Replication
D014764:Viral Proteins; D019915:DNA Primase; D004265:DNA Helicases